Not recruiting
Chronic kidney disease
Not recruitingStudy of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease
Registered drug
Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease
Registered drug
- Disease:Chronic kidney disease
- Substances:BI 690517Empagliflozin
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:BI 690517
- Sponsor:Boehringer Ingelheim International GmbH



